ED is prevalent in hemodialysis (HD) patients, and closely related to poor sleep and depression. Efficacy of treating ED either with sildenafil or vardenafil has been shown to be beneficial in ameliorating concomitant depression in non-HD patients. It is yet to be shown whether treatment of ED with a PDE-5 inhibitor would improve poor sleep in HD patients. We aimed to compare the effects of sildenafil and vardenafil on sleep quality and depression in HD patients with ED. A total of 32 maintenance HD patients with ED randomized into two groups to receive either sildenafil or vardenafil for 4 weeks. After a 2-week washout and a crossover, each group received the other drug for another 4-week period. Sleep quality and depression were evaluated via post-sleep inventory (PSI) and Beck's depression inventory (BDI), respectively, at baseline and at the end of the treatment. Sildenafil and vardenafil both improved PSI and BDI scores significantly compared with pretreatment values. However, there was no difference between sildenafil and vardenafil with respect to these parameters. PDE-5 inhibitors, sildenafil and vardenafil, caused a significant improvement in sleep quality and depression in this cohort of HD patients with ED.
Introduction
ED is prevalent among hemodialysis (HD) patients, and closely associated with poor sleep quality and depression. Prevalence rates ranging between 70 and 82% have been reported. 1 Sildenafil, a PDE-5 inhibitor, has been shown to be very effective against ED in a number of underlying causes to date. 2 Sildenafil has also been tested and shown to be effective in HD patients. 1 However, up to 20% of patients are resistant to sildenafil treatment including severe diabetic patients. 3 Vardenafil, a more potent PDE-5 inhibitor, has been effective in sildenafil-unresponsive patients when compared with placebo. 4 However, safety and efficacy of vardenafil are yet to be evaluated in HD population.
The importance of depression in HD patients is twofold: it is very common and presence of depression is an independent determinant of mortality. There is a close relation between depression and ED, each feeding the other. 5 Thus, treating one condition, whereas not considering the other may result in failure. Furthermore, selective serotonin reuptake inhibitors are associated with development of ED per se. 6 A few studies have investigated the effect of treatment of ED with sildenafil and vardenafil on concomitant untreated depression and showed favorable results. However, to the best of our knowledge, this beneficial effect has never been studied in HD patients. 7, 8 Depression and ED are both associated with poor sleep quality. 9, 10 However, it is not known yet whether treatment of ED with PDE-5 inhibitors would be beneficial in terms of sleep quality in HD patients.
In this present study, we aimed to compare the effects of sildenafil and vardenafil on depression and sleep quality in HD patients with ED.
Materials and methods
This is an open-label, randomized, prospective, crossover study that was conducted at the HD unit of our university hospital. A total of 40 adult male patients undergoing maintenance HD and in a stable heterosexual relationship in the previous 6 months with a clinical diagnosis of ED X6 months were included in the study. Exclusion criteria included current treatment of ED regardless of drug or method, alcohol or drug abuse, inability to follow study instructions, major hematologic or hepatic abnormalities, myocardial infarction in the preceding 6 months and concomitant treatment with nitrate or derivatives, uncontrolled hypertension or symptomatic hypotension, penile anatomic deformity, bleeding diathesis and active peptic ulcer disease, being scheduled to renal transplantation or another surgical procedure, any drug treatment for insomnia and depression, and active psychiatric disease such as psychosis. Eight patients were excluded from the study, in which exclusion reasons were: scheduling for renal transplantation in one, penile prosthesis in one, parathyroidectomy for secondary hyperparathyroidism in one and refusal to participate in the study in five patients. Thus, the study commenced with 32 patients.
ED was evaluated by the International Index of Erectile Function (IIEF-5) survey, and results regarding efficacy of sildenafil and vardenafil on ED and quality of life were reported elsewhere. 11 In this current report, we evaluated changes in depression and sleep quality with treatment of ED either with sildenafil or vardenafil.
ED was defined as the inability to achieve or maintain a penile erection sufficient for satisfactory sexual intercourse. The diagnosis was confirmed with a score of 21 or less in IIEF-5. 12 Drugs were selfadministered 45 min before sexual intercourse once per week. The study complied with the ethical principles of the Helsinki Declaration, and the protocol was approved by our Institutional Review Board. All patients were enrolled after signing informed consent form. Figure 1 depicts schematic representation of the study design that consisted of two four-week phases. During a 2-week run-in phase, patients were instructed to complete study forms, and blood samples were collected to determine biochemistry work-up and complete blood count. Dialysis adequacy (Kt/V) was determined from dialysis center patient charts. A total of 32 patients were randomized into either sildenafil or vardenafil groups by opening prenumbered sealed opaque envelopes containing a computer-generated randomization sequence.
We compared sildenafil and vardenafil in terms of effects on ED, depression and sleep quality via the IIEF-5, Beck's Depression Inventory (BDI) and Post-Sleep Inventory (PSI) surveys, respectively. These surveys were self-administered at appropriate points as per study protocol. Following are the composition and interpretation of applied surveys: BDI This is a 21-question multiple-choice self-report inventory, one of the most widely used instruments for measuring the severity of depression. BDI gives more emphasis on cognitive and emotional aspects of depression than somatic aspects namely, anorexia, diminished libido and weight loss. Thus, it is an appropriate tool to evaluate depression in patients with somatic diseases. 13 It has been validated in Turkish population.
14 Each item in the inventory can take points ranging from 0 to 3. The minimum and maximum scores of the scale are 0 and 63, respectively. The higher the score, the more severe the signs of depression. In Turkish population, 15 points and above is accepted as an indicator of depression.
PSI
This survey has been devised by Webb et al., 15 and adapted to Turkish HD population to evaluate sleep problems. 16 It consists of 12 questions in three groups dealing with pre-, during and post-sleep periods. The aim is to classify the patient's understanding about his or her sleep quality in terms of feelings at bedtime, quality of nocturnal sleep and feelings at awakening. A PSI score of 0 reflects a positive opinion about the patient's sleep quality, whereas a score of 1 reflects a negative opinion. Total PSI scores of 0, 1-3, 4-6, 7-9 and 10-12 indicate no sleep problem, mild, moderate, severe and very severe sleep problems, respectively. PSI is a validated tool in evaluating sleep quality in dialysis patients. 17 
Statistical analyses
The data were evaluated using the SPSS 15 
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Y Solak et al means ± standard deviation. For statistical analysis, the Friedman test was used for four measurements because differences among groups were not distributed normally. In cases of significant differences among measurements, the Bonferroni-adjusted Wilcoxon-signed rank test was used as post hoc analysis. In all analyses, a P-value o0.05 was accepted as statistically significant.
Results
Sociodemographic characteristics and laboratory data of the entire study population are shown in Table 1 . Cumulatively, in all 32 patients who received sildenafil and vardenafil, there was a statistically significant improvement in BDI and PSI scores at the end of the study when compared with pretreatment values (Table 2) . With favorable effects of sildenafil and vardenafil on sleep quality and depression, there was no statistically significant difference between the drugs in terms of these parameters. BDI scores showed a negative correlation with age, hemoglobin and serum albumin level, despite not statistically significant. However, there was a significant negative correlation between BDI scores and dialysis adequacy (Kt/V), and IIEF-5 score. Inadequate HD seemed to have an association with depression. There appeared a positive correlation between BDI score and all three domains of PSI. The higher the BDI score (means more severe depressive symptoms), the poorer was the sleep quality. There was no correlation of PSI with any of the studied laboratory parameters.
Discussion
The main result of this study was the beneficial effects of PDE-5 inhibitor therapy on concomitant untreated depression and poor sleep in HD patients.
Depression is prevalent among dialysis patients.
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Various studies using self-report questionnaires reported prevalence of depressive symptoms in end-stage renal disease patients in a range from 15% to 60%.
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In addition to being frequently encountered comorbidities in end-stage renal disease patients, depression and ED are clearly associated. 5 Sexual dysfunction is common in men who have depression, because loss of interest in pleasurable activities including sexual activity is one of the diagnostic criteria of major depressive disorder. In Massachusetts Male Aging Study, the prevalence of ED correlated strongly with advancing age, and in all age groups, ED was more common in the upper quartiles of depression scores. 20 Relationship between ED and depression is bidirectional, the two conditions reinforce each other in a downward spiral. 5 Selective serotonin reuptake inhibitors are quite effective in improving depressive symptoms; however, improvement of ED as a result of antidepressant therapy is seldom seen. Furthermore, selective serotonin reuptake inhibitors may cause sexual dysfunction per se. 6 Treatment of depression in a HD patient may improve depressive symptoms. 18 However, when a depressive HD patient had concurrent ED, a common scenario in real life, selective serotonin reuptake inhibitors may even worsen ED, which in turn affects mood adversely, causing a vicious cycle.
Two recent studies assessed effect of treatment of ED with either sildenafil or vardenafil on concomitant untreated depression. Seidman et al. 7 randomized patients with ED into sildenafil and placebo arms, and assessed effects on otherwise untreated depressive symptoms. The authors found an overall improvement in mood of patients with sildenafil treatment when compared with placebo similar to that seen with traditional antidepressant therapy. Efficacy of vardenafil in this context has also been demonstrated in another study. 8 The results of the present study confirmed the beneficial effect of treatment of ED with a PDE-5 inhibitor on depressive symptoms in HD patients. Despite BDI scores, in other words, severity of depressive symptoms, were not very high in our study cohort, treatment with a PDE-5 inhibitor showed beneficial results in this respect. Testing this beneficial effect with PDE-5 inhibitors in patients with more severe depressive symptoms and/or clinically diagnosed depression is a clear need. Sildenafil and vardenafil were equally effective in ameliorating depressive symptoms.
The prevalence of various sleep disorders, including sleep apnea syndrome, insomnia and frequent awakenings, among dialysis patients ranges between 40 and 80% depending on the assessment method, type of population and the particular type of sleep disorder studied. 21 Sleep disorders are closely related to depression both in the general population and HD patients. 9 Disturbed sleep is among the cardinal symptoms of major depression. It has been estimated that 90% of patients with depression complain about sleep quality. 22 Sleep disorders are associated not only with impaired quality of life and cardiovascular morbidity, but also with all-cause mortality. 9 An association between sleep disorders and ED has been demonstrated, and some groups suggested that treatment of a sleep disorder such as obstructive sleep apnea syndrome (OSAS) may reverse ED. 10, 23 Patients presenting with ED also report various symptoms that are consistent with a sleep disorder. 24 Recent studies have shown that 75% of patients with OSAS treated with continuous positive airway pressure (CPAP) experienced improvement to some extent in ED severity. 25 In a very recent study, Taskin et al. reported a high correlation between severe OSAS and presence of ED and high response rate among patients with ED to CPAP therapy. 26 Similarly, Margel et al. also found that in contrast to mild-to-moderate OSAS, only severe OSAS was clearly associated with ED. 27 A number of studies suggested improvement in ED with treatment of OSAS by various treatment modalities, including CPAP and oral appliances. 25 Perimenis et al. showed that combination of sildenafil and CPAP was superior to CPAP alone in the treatment of ED, whereas Roizenblatt et al. reported worsened respiratory and desaturation events with a single dose of sildenafil. 28, 29 Treatment of ED in patients with severe OSAS should be a combination of a sleep apnea treatment modality and PDE-5 inhibitor. However, in the latter study, sildenafil was not used with purpose of treating ED and patients had severe OSAS. A hypothetical mechanism was proposed that increased availability of nitric oxide by PDE-5 inhibitor therapy may have caused collapse of upper respiratory tract muscles, which also had nitric oxide receptors. Thus, generalization cannot be made regarding patients with less severe OSAS.
Our results showed that both sildenafil and vardenafil were equally effective with respect to improvements in sleep quality when used with purpose of treating ED in HD patients. The exact mechanism is not clear at the time; however, both direct and indirect effects may have a role. Treatment of ED with a PDE-5 inhibitor may lead to amelioration of depression and thus benefit sleep quality, given the close relationship between depression and poor sleep.
This study has some limitations that deserve mention. First, we did not use an objective test to diagnose the specific type of sleep disorder present. Instead, we used a sleep quality questionnaire that measured general quality of sleep, not the particular type. Thus, our cohort may have included a heterogenous group in terms of various sleep disorders. Nevertheless, study population globally benefited from PDE-5 inhibitor therapy. Secondly, we did not diagnose clinical depression via DSM-IV criteria, rather we screened presence and severity of depressive symptoms by using BDI scores. We did not use any objective diagnostic method such as penile doppler to diagnose ED. Nevertheless, our cohort represents an average-risk HD population in terms of ED excluding ED that was developed after prostatectomy and spinal cord compression. Our relatively small sample size should also be considered as a limitation. This small sample size may have hampered the ability of the study to show a significant difference, if any, between the two PDE-5 inhibitors in terms of effects on poor sleep and depression. Despite limitations, this study is the first to demonstrate the beneficial effects of sildenafil and vardenafil on untreated depression and sleep disturbance in HD patients with ED.
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Conclusions
In conclusion, depression, sleep disorder and ED triad is common, and individual components are closely interrelated in HD patients. This study was the first to show that treatment of ED either with sildenafil or vardenafil may benefit end-stage renal disease patients in terms of concomitant depression and sleep disorder.
